Cedars-Sinai Cancer investigators found that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
The European Medicines Agency has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.
